Medical Advisors

Micregen’s scientific, clinical and regulatory advisors consist of several drug development experts who provide advice to ensure Micregen’s Secretomix® products build the required efficacy and safety profile in preclinical development to meet regulatory requirements and progress to clinical trial.

Prof. Alan Boyd BSc, MB, ChB, FRSB, FRCP, FFPM

Medical Director

A graduate in Biochemistry and Medicine from the University of Birmingham, and a Fellow and the 2018 President of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. Alan was previously Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at The Royal College of Physicians.

In November 2009, he was appointed an Honorary Professor at the College of Medical and Dental Sciences at the University of Birmingham Medical School in recognition of his expertise in medicines development. In October 2014, he was elected as a fellow of the Royal Society of Biology.

Prof. Kate Costeloe CBE, BChir MB

Advisory Board Chair

Prof. Kate Costeloe CBE, BChir MB, Advisory Board Chair, retired as a neonatologist, Professor of Paediatrics at Queen Mary University of London, Professor of Paediatrics at Barts and the London Hospitals and Honorary Consultant at Homerton University Hospital, London.

Kate led several important research projects in the field of neonatology, including outcomes following extremely preterm birth and the prevention of necrotising enterocolitis. She is Co-Chair of the Steering Board of the Neonatal Data Analysis Unit at Imperial College London.

In 2016 Kate was awarded the James Spence Medal for outstanding contributions to the advancement or clarification of paediatric knowledge. It is the highest honour bestowed by The Royal College of Paediatrics and Child Health.

Dr Augusto Zani MD, PhD

Research & Clinical Advisor

Dr Zani is a medically qualified doctor who completed his paediatric surgical training at Sapienza University of Rome, Italy. He is also a doctor in research, having gained his PhD from University College London, U.K., where his investigations focused on the development of novel stem cell therapies. It was during his time at UCL that Augusto made one of the landmark discoveries showing the potential of amniotic fluid stem cells as a therapy.

Thereafter, he took up a fellowship in neonatal surgery at the Hospital for Sick Children (SickKids), Toronto, Canada, in 2014. Augusto’s achievements were recognised in 2016 when he was appointed as a Staff Surgeon in the Division of General and Thoracic Surgery. He has made several major discoveries that advance our understanding of the causes of several diseases, including lung conditions, and is working with Micregen to identify new therapeutic avenues as treatments.

Robert Smith BSc (Hons), MSc, Pg Dip, FRPharmS

Qualified Person

Qualified Person (QP), Quality Systems Management & cGMP Auditor, QP Assessor for the Royal Pharmaceutical Society of Great Britain and holds the office of Vice-Chair of the Royal Pharmaceutical Society panel of QP Assessors and appointed as a Fellow of the Royal Pharmaceutical Society.

Experienced in the life sciences industry since 1984, holding roles including Global Head of Quality for Genzyme’s Clinical Supplies Department and past Chair of Investigational Product COP (IP COP) Council.

Robert was the co-author of the Supply Chain Management Chapter of the ISPE Good Practice Guide for the Development of Investigational Biological Products and played a leading role in the production of the ISPE Good Practice Guide on Interactive Response Technology.



David was employed by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for over twenty-five years. He is a European Registered Toxicologist and a Fellow of the British Toxicology Society as well as a Chartered Biologist and a Fellow of the Royal Society of Biology. He also lectures at the University of Surrey and the University of Wales.

David assessed every UK application for potential COVID-19 vaccines and treatments. His many years of experience at the MHRA provide invaluable insight for Micregen to help take its products into clinical trials.



Sarah is the founder of QRC Consultants and has over twenty years industry experience covering all aspects of regulatory affairs (Scientific Advice, Orphan Drug Designations, Clinical Trial Applications and Marketing Authorisation Applications).



Jane has world-leading expertise in reproductive toxicology and the safety assessment of pharmaceuticals. She has helped draft international testing guidelines for pharmaceuticals.

Get in touch with us